More importantly, IFNγ can rescue CLL cells from apoptosis triggered by targeted therapies, such as ibrutinib [16], and it is likely implicated in resistance to venetoclax through an Mcl-1–dependent mechanism [14, 17, 18]. The gene discussed is IFNG; the disease is B-cell chronic lymphocytic leukemia.